Bavarian Nordic AS (BAVA):企業の財務・戦略的SWOT分析

GlobalDataが発行した調査報告書(DATA904C4821)
◆英語タイトル:Bavarian Nordic AS (BAVA) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C4821
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年8月
◆ページ数:49
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Bavarian Nordic AS (BAVA) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Bavarian Nordic A/S (Bavarian Nordic) is a biotechnology company that develops, manufactures and commercializes cancer immunotherapies and vaccines for infectious diseases. The company develops its products using poxvirus-based technology platforms including vaccinia-fowlpox (VF)-TRICOM and modified vaccinia ankara – bavarian nordic (MVA-BN). Its pipeline products are intended for the treatment of smallpox, prostate cancer, bladder cancer, solid tumors, chronic HPV infection, marburg and ebola infections, and others. Bavarian Nordic has collaboration with US government and various institutes, to develop its product candidates for the treatment of cancer and infectious diseases. It has a presence in the US, Denmark and Germany. Bavarian Nordic is headquartered in Kvistgaard, Denmark.

Bavarian Nordic AS Key Recent Developments

Aug 16,2018: Bavarian Nordic announces first half 2018 results
Aug 09,2018: Bavarian Nordic granted EUR 30 million loan from The European Investment Bank
May 31,2018: Bavarian Nordic Appoints Henrik Juuel As Chief Financial Officer
May 24,2018: Bavarian Nordic Announces Interim Results for the First Three Months of 2018
May 16,2018: Bavarian Nordic Announces Acceptance of Abstracts and Oral Presentation at the American Society of Clinical Oncology Annual Meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Bavarian Nordic A/S – Key Facts 6
Bavarian Nordic A/S – Key Employees 7
Bavarian Nordic A/S – Key Employee Biographies 8
Bavarian Nordic A/S – Major Products and Services 9
Bavarian Nordic A/S – History 10
Bavarian Nordic A/S – Company Statement 12
Bavarian Nordic A/S – Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Section 2 – Company Analysis 15
Company Overview 15
Bavarian Nordic A/S – Business Description 16
R&D Overview 16
Bavarian Nordic A/S – SWOT Analysis 17
SWOT Analysis – Overview 17
Bavarian Nordic A/S – Strengths 17
Bavarian Nordic A/S – Weaknesses 18
Bavarian Nordic A/S – Opportunities 19
Bavarian Nordic A/S – Threats 20
Bavarian Nordic A/S – Key Competitors 21
Section 3 – Company Financial Ratios 22
Financial Ratios – Capital Market Ratios 22
Financial Ratios – Annual Ratios 23
Performance Chart 26
Financial Performance 26
Financial Ratios – Interim Ratios 27
Financial Ratios – Ratio Charts 28
Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances 29
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30
Bavarian Nordic A/S, Recent Deals Summary 31
Section 5 – Company’s Recent Developments 32
Aug 16, 2018: Bavarian Nordic announces first half 2018 results 32
Aug 09, 2018: Bavarian Nordic granted EUR 30 million loan from The European Investment Bank 34
May 24, 2018: Bavarian Nordic Announces Interim Results for the First Three Months of 2018 35
May 16, 2018: Bavarian Nordic Announces Acceptance of Abstracts and Oral Presentation at the American Society of Clinical Oncology Annual Meeting 37
Mar 16, 2018: Bavarian Nordic Announces Partnership with U.S. Department of Defense to Combat Equine Encephalitis Virus 38
Mar 12, 2018: Bavarian Nordic Announces Annual Report 2017 39
Mar 12, 2018: Bavarian Nordic Awards Restricted Stock Units to Executive Management 41
Nov 08, 2017: Bavarian Nordic Announces Interim Results for the First Nine Months of 2017 42
Aug 25, 2017: Bavarian Nordic Announces First Half 2017 Results 43
May 10, 2017: Bavarian Nordic Announces Appointment of Dr. Tommi Kainu as Chief Business Officer 44
Section 6 – Appendix 45
Methodology 45
Ratio Definitions 45
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Bavarian Nordic A/S, Key Facts 6
Bavarian Nordic A/S, Key Employees 7
Bavarian Nordic A/S, Key Employee Biographies 8
Bavarian Nordic A/S, Major Products and Services 9
Bavarian Nordic A/S, History 10
Bavarian Nordic A/S, Other Locations 14
Bavarian Nordic A/S, Subsidiaries 14
Bavarian Nordic A/S, Key Competitors 21
Bavarian Nordic A/S, Ratios based on current share price 22
Bavarian Nordic A/S, Annual Ratios 23
Bavarian Nordic A/S, Annual Ratios (Cont...1) 24
Bavarian Nordic A/S, Annual Ratios (Cont...2) 25
Bavarian Nordic A/S, Interim Ratios 27
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30
Bavarian Nordic A/S, Recent Deals Summary 31
Currency Codes 45
Capital Market Ratios 45
Equity Ratios 46
Profitability Ratios 46
Cost Ratios 47
Liquidity Ratios 47
Leverage Ratios 48
Efficiency Ratios 48

List of Figures
Bavarian Nordic A/S, Performance Chart (2013 - 2017) 26
Bavarian Nordic A/S, Ratio Charts 28
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Bavarian Nordic AS (BAVA):企業の財務・戦略的SWOT分析(Bavarian Nordic AS (BAVA) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆